Novo Nordisk receives FDA approval for Norditropin® FlexPro® for growth hormone treatment

Novo NordiskNovo Nordisk announced that the US Food and Drug Administration (FDA) has approved Norditropin® FlexPro®, a new prefilled growth hormone injection pen to be used by children and adults.

Norditropin® FlexPro® has a unique new dosing mechanism, a user-friendly design which makes it easy to learn and use, and an audible click that confirms that the dose has been delivered. Norditropin® FlexPro® requires no reconstitution and no loading of cartridges. Norditropin® FlexPro® is available in 5 mg/1.5 ml, 10 mg/1.5 ml and 15 mg/1.5 ml pens.

In a handling study[1], 100% of patients found it easy to learn how to use Norditropin® FlexPro®. Ninety-nine percent of patients found it easy to push the button to dose, and 97% felt confident the correct dose was delivered.

"During our 20 years providing Norditropin® growth hormone, we have listened to patients and we understand the importance of providing simple, hassle-free patient care," says Pablo de Mora, global vice president of Growth Hormone Treatment in Novo Nordisk. "With the advantages of our new Norditropin® FlexPro® we are convinced that daily injections will be made even simpler, so patients are better able to achieve their individual treatment goals."

Novo Nordisk introduced Norditropin® in 1988; the first liquid growth hormone formulation, Norditropin® SimpleXx®, in 1999; and the first prefilled growth hormone pen, Norditropin NordiFlex®, in 2004. The introduction of Norditropin® FlexPro® represents the latest advance in growth hormone pens building on this heritage.

About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. For more information, visit novonordisk.com.

1. Fuchs GS et al. Clin Ther 2009; 31 (12)

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]